Single center experience with hyperthermic intraperitoneal chemotherapy

Woo Ram Kim, Hyuk Hur, Byung Soh Min, Seung Hyuk Baik, Kang Young Lee, Namkyu Kim

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have been proposed for controlling peritoneal seeding metastasis in some kinds of cancers, including those of colorectal origin, but their safety and oncological benefits are subjects of debate. We present our early experience with those procedures. Methods: Data were retrospectively collected from all patients with peritoneal carcinomatosis (PC) and pseudomyxoma peritonei (PMP) treated using CRS and HIPEC at Yonsei Cancer Center between July 2014 and July 2015. Short-Term outcomes and risk factors for postoperative complications were analyzed. Results: Twenty-Three patients with PC (n = 18) and PMP (n = 5) underwent CRS and HIPEC. Median follow-up and age were 2 months and 54 years, respectively. The median peritoneal carcinomatosis index score was 15, and CC0-1 was achieved in 78.3% of all patients. The median operation time and bleeding loss were 590 minutes and 570 mL, respectively. Grade-IIIa/grade-IIIb complications occurred in 4.3% (n = 1)/26.1% (n = 6) of the patients within 30 days postoperatively, and no 30-day mortalities were reported. Factors related to postoperative complications with CRS and HIPEC were number of organ resection (P = 0.013), longer operation time (P < 0.001), and amount of blood loss (P = 0.003). All patients treated with cetuximab for recurred colorectal cancer had grade-III postoperative complication. Conclusion: Our initial experience with CRS and HIPEC presented about 30% grade-III postoperative complications. Therefore, expert surgeons need to perform those procedures with great caution in selected patients who might benefit from it.

Original languageEnglish
Pages (from-to)16-22
Number of pages7
JournalAnnals of Coloproctology
Volume33
Issue number1
DOIs
Publication statusPublished - 2017 Feb 1

Fingerprint

Drug Therapy
Pseudomyxoma Peritonei
Carcinoma
Bleeding Time
Colorectal Neoplasms
Neoplasms
Neoplasm Metastasis
Safety
Mortality

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cite this

Kim, Woo Ram ; Hur, Hyuk ; Min, Byung Soh ; Baik, Seung Hyuk ; Lee, Kang Young ; Kim, Namkyu. / Single center experience with hyperthermic intraperitoneal chemotherapy. In: Annals of Coloproctology. 2017 ; Vol. 33, No. 1. pp. 16-22.
@article{5329d1220cbc42dbb7fb0879c308876e,
title = "Single center experience with hyperthermic intraperitoneal chemotherapy",
abstract = "Purpose: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have been proposed for controlling peritoneal seeding metastasis in some kinds of cancers, including those of colorectal origin, but their safety and oncological benefits are subjects of debate. We present our early experience with those procedures. Methods: Data were retrospectively collected from all patients with peritoneal carcinomatosis (PC) and pseudomyxoma peritonei (PMP) treated using CRS and HIPEC at Yonsei Cancer Center between July 2014 and July 2015. Short-Term outcomes and risk factors for postoperative complications were analyzed. Results: Twenty-Three patients with PC (n = 18) and PMP (n = 5) underwent CRS and HIPEC. Median follow-up and age were 2 months and 54 years, respectively. The median peritoneal carcinomatosis index score was 15, and CC0-1 was achieved in 78.3{\%} of all patients. The median operation time and bleeding loss were 590 minutes and 570 mL, respectively. Grade-IIIa/grade-IIIb complications occurred in 4.3{\%} (n = 1)/26.1{\%} (n = 6) of the patients within 30 days postoperatively, and no 30-day mortalities were reported. Factors related to postoperative complications with CRS and HIPEC were number of organ resection (P = 0.013), longer operation time (P < 0.001), and amount of blood loss (P = 0.003). All patients treated with cetuximab for recurred colorectal cancer had grade-III postoperative complication. Conclusion: Our initial experience with CRS and HIPEC presented about 30{\%} grade-III postoperative complications. Therefore, expert surgeons need to perform those procedures with great caution in selected patients who might benefit from it.",
author = "Kim, {Woo Ram} and Hyuk Hur and Min, {Byung Soh} and Baik, {Seung Hyuk} and Lee, {Kang Young} and Namkyu Kim",
year = "2017",
month = "2",
day = "1",
doi = "10.3393/ac.2017.33.1.16",
language = "English",
volume = "33",
pages = "16--22",
journal = "Annals of Coloproctology",
issn = "2287-9714",
publisher = "Korean Society of Coloproctology",
number = "1",

}

Single center experience with hyperthermic intraperitoneal chemotherapy. / Kim, Woo Ram; Hur, Hyuk; Min, Byung Soh; Baik, Seung Hyuk; Lee, Kang Young; Kim, Namkyu.

In: Annals of Coloproctology, Vol. 33, No. 1, 01.02.2017, p. 16-22.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Single center experience with hyperthermic intraperitoneal chemotherapy

AU - Kim, Woo Ram

AU - Hur, Hyuk

AU - Min, Byung Soh

AU - Baik, Seung Hyuk

AU - Lee, Kang Young

AU - Kim, Namkyu

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Purpose: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have been proposed for controlling peritoneal seeding metastasis in some kinds of cancers, including those of colorectal origin, but their safety and oncological benefits are subjects of debate. We present our early experience with those procedures. Methods: Data were retrospectively collected from all patients with peritoneal carcinomatosis (PC) and pseudomyxoma peritonei (PMP) treated using CRS and HIPEC at Yonsei Cancer Center between July 2014 and July 2015. Short-Term outcomes and risk factors for postoperative complications were analyzed. Results: Twenty-Three patients with PC (n = 18) and PMP (n = 5) underwent CRS and HIPEC. Median follow-up and age were 2 months and 54 years, respectively. The median peritoneal carcinomatosis index score was 15, and CC0-1 was achieved in 78.3% of all patients. The median operation time and bleeding loss were 590 minutes and 570 mL, respectively. Grade-IIIa/grade-IIIb complications occurred in 4.3% (n = 1)/26.1% (n = 6) of the patients within 30 days postoperatively, and no 30-day mortalities were reported. Factors related to postoperative complications with CRS and HIPEC were number of organ resection (P = 0.013), longer operation time (P < 0.001), and amount of blood loss (P = 0.003). All patients treated with cetuximab for recurred colorectal cancer had grade-III postoperative complication. Conclusion: Our initial experience with CRS and HIPEC presented about 30% grade-III postoperative complications. Therefore, expert surgeons need to perform those procedures with great caution in selected patients who might benefit from it.

AB - Purpose: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have been proposed for controlling peritoneal seeding metastasis in some kinds of cancers, including those of colorectal origin, but their safety and oncological benefits are subjects of debate. We present our early experience with those procedures. Methods: Data were retrospectively collected from all patients with peritoneal carcinomatosis (PC) and pseudomyxoma peritonei (PMP) treated using CRS and HIPEC at Yonsei Cancer Center between July 2014 and July 2015. Short-Term outcomes and risk factors for postoperative complications were analyzed. Results: Twenty-Three patients with PC (n = 18) and PMP (n = 5) underwent CRS and HIPEC. Median follow-up and age were 2 months and 54 years, respectively. The median peritoneal carcinomatosis index score was 15, and CC0-1 was achieved in 78.3% of all patients. The median operation time and bleeding loss were 590 minutes and 570 mL, respectively. Grade-IIIa/grade-IIIb complications occurred in 4.3% (n = 1)/26.1% (n = 6) of the patients within 30 days postoperatively, and no 30-day mortalities were reported. Factors related to postoperative complications with CRS and HIPEC were number of organ resection (P = 0.013), longer operation time (P < 0.001), and amount of blood loss (P = 0.003). All patients treated with cetuximab for recurred colorectal cancer had grade-III postoperative complication. Conclusion: Our initial experience with CRS and HIPEC presented about 30% grade-III postoperative complications. Therefore, expert surgeons need to perform those procedures with great caution in selected patients who might benefit from it.

UR - http://www.scopus.com/inward/record.url?scp=85015884543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015884543&partnerID=8YFLogxK

U2 - 10.3393/ac.2017.33.1.16

DO - 10.3393/ac.2017.33.1.16

M3 - Article

VL - 33

SP - 16

EP - 22

JO - Annals of Coloproctology

JF - Annals of Coloproctology

SN - 2287-9714

IS - 1

ER -